All Videos

Joseph Gatti, DMSc, MPAS, MBA, PA-C, discusses the impact of social media and AI on dermatology, urging professionals to adapt and educate in a rapidly evolving landscape.

Heather Goff, MD, MPH, discusses her role as SDPA Medical Director and the vital collaboration between dermatology PAs and physicians at the 2025 fall conference.

Discover how the SDPA Diplomate Fellowship has evolved with innovative learning tools, enhancing education for dermatology PAs at the Fall 2025 conference.

Heather Goff, MD, MPH, shares vital insights on lifestyle, ethics, and cutaneous lymphomas at SDPA Fall 2025, highlighting the future of dermatology.

Joseph Gatti, DMSc, MPAS, MBA, highlights the importance of collaboration between PAs and dermatologists, emphasizing mutual respect and the role of PAs in enhancing patient care.

Andrew Baker, MBA, MPAS, PA-C, discusses leadership and inclusivity in dermatology at the SDPA Fall Conference, emphasizing collaboration and member engagement for future growth.

Harrison Nguyen, MD, shares groundbreaking insights on CSU, vasculitis, and bullous diseases at the SDPA Fall 2025 conference, enhancing dermatologic education.

Shannon Trotter, DO, explores social media's impact on dermatology, lichenoid disorders, and granuloma annulare at SDPA Fall 2025.

Explore how a groundbreaking initiative by Hayden Middleton, PA-C, bridges dermatology and nutrition, enhancing patient care and clinician fulfillment.

Kassandra Holzem, MD, shares vital insights on dermatology red flags and GVHD management, enhancing oncology care at SDPA Fall 2025.

Kristine Kucera, PA-C, MPAS, DHS, reflects on her impactful 30-year career and celebrates the evolution of dermatology PAs at the SDPA Fall 2025 conference.

Explore the latest insights on psoriatic arthritis and psoriasis management from Shikha Singla, MD, emphasizing multidisciplinary care and early screening strategies.

SDPA Emerging Scholars share insights on mentorship and professional growth, highlighting the importance of collaboration in dermatology.

Panelists discuss how twice-daily dosing represents the biggest adherence challenge and how simplifying regimens from multiple location-specific medications to single versatile treatments significantly improves adherence, with once-daily formulations being much more manageable for busy families.

Panelists discuss how roflumilast demonstrated 25% Investigator’s Global Assessment (IGA) success at 4 weeks in the Integument PED trial with impressive long-term results showing 73% Eczema Area and Severity Index (EASI-75) achievement at 56 weeks, while highlighting its excellent tolerability profile with no black box warning, no folliculitis, and minimal stinging compared with previous phosphodiesterase-4 inhibitors.

Yasmine Kirkorian, MD, shares insights on pediatric dermatology advancements and genetic skin disorders at SDPA Fall 2025, emphasizing early diagnosis and innovative therapies.

Marc Serota, MD, discusses using ruxolitinib cream to safely maintain repigmentation, minimize steroid-related adverse effects, and enhance outcomes when combined with phototherapy.

Explore insights from SDPA leaders Renata Block, DMSc, MMS, PA-C, and Sarah Vicari, MMS, PA-C, on mentorship, volunteerism, and fostering growth for PAs.

Panelists discuss how the AHEAD recommendations establish structured, patient-centered treatment targets that help clinicians achieve measurable and lasting success in atopic dermatitis management.

Hilary Baldwin, MD, introduces the series and reviews acne pathogenesis, mechanisms of topical therapies, and key barriers to adherence in everyday practice.

A panelist discusses how the rise of convenient and accessible oral therapies is poised to redefine systemic treatment strategies, payer decisions, and clinical guidelines in dermatology.

Allergan Aesthetics pioneers regenerative skincare through secretome science, enhancing skin health with fibroblast-derived exosomes for transformative results.

Lindsay Ackerman, MD, explains the importance of transparency when prescribing medications with boxed warnings.

Discover how Prithwiraj Maitra, PhD, advances skin care innovation with exosomes, emphasizing scientific validation and ingredient transparency in cosmetic formulations.

New findings from LEO Pharma reveal chronic hand eczema affects 1 in 10 adults, highlighting the need for improved recognition and management in dermatology.

Advances in atopic dermatitis research could bring longer-lasting biologics and improved treatment adherence.

Panelists discuss how tapinarof showed strong efficacy in the Adoring trials, with 45% to 46% Investigator’s Global Assessment (IGA) success and 55% to 60% Eczema Area and Severity Index (EASI-75) achievement at 8 weeks. However, they question real-world adherence to daily application over such extended periods and note folliculitis as a notable adverse effect occurring in over 5% of patients.

Panelists discuss how ruxolitinib cream demonstrated impressive efficacy in the TRU83 trial, with over 50% of patients achieving near-complete clearance at 8 weeks using the 1.5% formulation, while acknowledging that the Janus kinase (JAK) inhibitor’s broad mechanism makes its effectiveness unsurprising despite concerns about the boxed warning.

The Phoenix-based dermatologist encourages innovative and patient-tailored strategies to optimize pigment restoration.

At Fall Clinical 2025, experts discussed the science behind oral IL-23 inhibition, potentially ending the injection-only era for psoriasis therapy.